- To investigating whether NBD peptide can promote tumor cell death in canine soft tissue sarcomas (STS) that have active NF-KB (signaling pathway) activity
- Confirmed/highly suspected diagnosis of STS obtained either via FNA or biopsy
- Dog is otherwise healthy
- No evidence of pulmonary metastasis
Basic study design:
- Screening visit - staging (blood work, urinalysis, chest x-rays) + incisional biopsy of the mass (to confirm diagnosis of sarcoma and also to determine whether the NF-KB pathway is overactive in the mass)
- If the overactive pathway is identified, then within one week:
- Daily tumor injections for 4 days with the NBD peptide (outpatient procedure)
- On day 5, the tumor is removed via definitive surgical excision (or if it is nonresectable, a second incisional biopsy will be obtained).
- Following surgery - recheck visits every 2 months for a total of 3 visits (physical exam and chest x-rays).
- Physical examinations throughout the course of the study.
- General health blood and urine tests at screening and one day after the last NBD peptide administration.
- Chest x-rays at screening and every 2 months there-after for a total of 6 months.
- Two biopsies of the tumor performed under light sedation or general anesthetic.
- Immunohistochemical analysis of the tumor (to determine NF-kappaB expression).
- $300 towards definitive surgery (to be performed one day following the last NBD peptide administration. This would replace the second biopsy procedure)
- Treatment of any toxicity your dog develops secondary to NBD peptide administration.
Please contact the VCIC at 215-573-0302 or email@example.com for more information about this study.